GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 5, 2011, Pages 1070-1072

  Holmberg, H ^a   Elm, T ^a   Karpf, D ^a   Tranholm, M ^a   Bjorn S E ^a   Stennicke, H ^a   Ezban, M ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEGYLATED RECOMBINANT BLOOD CLOTTING FACTOR 7A; MACROGOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; HEMOPHILIA; HEMOSTASIS; LETTER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AREA UNDER CURVE; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; FACTOR VIIA; GLYCOSYLATION; HEMOPHILIA A; HEMOSTASIS; HUMANS; MICE; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; TIME FACTORS;

EID: 79955662245     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04252.x     Document Type: Letter

References (16)

1. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
2. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008; 97: 4167-83.
3. Stone M, Harvey SB, Kisiel W, Foster D, Nelsestuen GL. Unusual benefits of macromolecular shielding by polyethylene glycol for reactions at the diffusional limit: the case of factor VIIai and tissue factor. Biochemistry 2002; 41: 15820-5.
4. Butenas S, Brummel KE, Branda RF, Paradis SG, Mann KG. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002; 99: 923-30.
5. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 2003; 101: 1864-70.
6. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
7. Allen GA, Persson E, Campbell RA, Ezban M, Hedner U, Wolberg AS. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-9.
8. Weeterings C, de Groot PG, Adelmeijer J, Lisman T. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 2008; 112: 3227-33.
9. Hoffman M, Monroe DM III. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Dis Mon 2003; 49: 14-21.
10. Stennicke HR, Ostergaard H, Bayer RJ, Kalo MS, Kinealy K, Holm PK, Sørensen BB, Zopf D, Bjørn SE. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-8.
11. Ghosh S, Sen P, Pendurthi UR, Rao LV. Activity and regulation of glycoPEGylated factor VIIa analogs. J Thromb Haemost 2008; 6: 1525-33.
12. Landskroner KA, Olson NC, Jesmok GJ. Thromboelastography measurements of whole blood from factor VIII-deficient mice supplemented with rFVIII. Haemophilia 2005; 11: 346-52.
13. Sørensen BB, Karpf DM, Groth AV, Bysted BV, Hermit MB, Tranholm M, Blain R, Kinealy K, Zopf D, Bayer RJ, Kalo MS, Stennicke HR. Effect of glycopegylation™ on the pharmacokinetic properties of FVIIa. J Thromb Haemost 2009; 5(Suppl. 2): P-T-102.
14. Møss J, Rosenholm A, Laurén A. Safety and pharmacokinetics of a long-acting glycopegylated rFVIIa derivate: a first human dose trail in healthy subjects. J Thromb Haemost 2009; 7(Suppl. 2): OC-WE-055.
15. Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008; 65: 3-11.
16. Holmberg HL, Lauritzen B, Tranholm M, Ezban M. Faster onset of effect and greater efficacy of NN1731, compared to rFVIIa, aPCC & FVIII in tail-bleeding in haemophilic mice. J Thromb Haemost 2009; 7: 1517-22.